SCHEMBL316933

SCHEMBL316933

CCCCCCOC(C(=O)O)(C(C(=O)O)C(=O)CCC)C(CCCCCC)(CCCCCC)C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 2/20 0.32
S1PR4 O95977 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
CES2 O00748 2/20 0.31
GPR84 Q9NQS5 4/20 0.30
NAAA Q02083 1/20 0.30
DGKA P23743 1/20 0.30
FFAR1 O14842 1/20 0.30
MEN1 O00255 1/20 0.30
HPGD P15428 1/20 0.30
RECQL P46063 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
SLC22A6 Q4U2R8 1/20 0.30
SLC22A8 Q8TCC7 1/20 0.30
PPARG P37231 1/20 0.30
PPARD Q03181 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9955144 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9956002 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9954639 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9954929 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9956324 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9955782 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9954828 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL9955180 1.00 PLA2G2C (0.32) PLA2G2CS1PR4S1PR1S1PR3CES2
SCHEMBL16341864 0.92
SCHEMBL9955644 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137591-A1 COMPOSITIONS AND DEVICES FOR CONTAINING MEDICAL FLUIDS ICU MEDICAL INC (US) 2026-05-21 US claimed
EP-3990037-B1 LAYERED COLLAGEN DRESSING WITH EXTENDED BACTERIA AND BIOFILM REDUCING CAPABILITIES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-06-19 EP claimed
EP-3713979-B1 MEDICAL DEVICES SOLVAY SPECIALTY POLYMERS IT (IT) 2024-03-06 EP claimed
US-20230399618-A1 METHODS, COMPOSITIONS, AND KITS FOR EXPANDING NATURAL KILLER CELLS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-12-14 US claimed
US-20230180741-A1 DEHP-Free Blood Storage and Methods of Use Thereof HEMANEXT INC. (US) 2023-06-15 US claimed
US-11672890-B2 Medical devices SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2023-06-13 US claimed
WO-2023086494-A1 METHODS, COMPOSITIONS, AND KITS FOR EXPANDING NATURAL KILLER CELLS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-05-19 WO claimed
EP-4149257-A2 DEHP-FREE BLOOD STORAGE AND METHODS OF USE THEREOF Hemanext Inc. (US) 2023-03-22 EP claimed
WO-2021231650-A2 DEHP-FREE BLOOD STORAGE AND METHODS OF USE THEREOF HEMANEXT INC. (US) 2021-11-18 WO claimed
US-11000551-B2 Red blood cell products and the storage of red blood cells in containers free of phthalate plasticizer FENWAL, INC. (US) 2021-05-11 US claimed
EP-1299048-A4 BIODEGRADABLE VEHICLES AND DELIVERY SYSTEMS OF BIOLOGICALLY ACTIVE SUBSTANCES SHUKLA ATUL J (US) 2005-09-28 EP claimed
EP-0996667-B1 PLASTIC COMPOSITIONS INCLUDING VITAMIN E FOR MEDICAL CONTAINERS AND METHODS FOR PROVIDING SUCH COMPOSITIONS AND CONTAINERS BAXTER INT (US) 2004-08-25 EP claimed
JP-2004511431-A 2004-04-15 JP claimed
US-20040018238-A1 Biodegradable vehicles and delivery systems of biolgically active substances SHUKLA ATUL J (US) 2004-01-29 US claimed
EP-1299048-A1 BIODEGRADABLE VEHICLES AND DELIVERY SYSTEMS OF BIOLOGICALLY ACTIVE SUBSTANCES Shukla, Atul J. (US) 2003-04-09 EP claimed
EP-0996677-B1 PLASTIC COMPOSITIONS FOR MEDICAL CONTAINERS AND METHODS FOR PROVIDING SUCH CONTAINERS AND FOR STORING RED BLOOD CELLS BAXTER INT (US) 2002-11-20 EP claimed
US-6432438-B1 BLENDING CO- OR HOMOPOLYMERS, PLASTICIZERS AND DRUGS TO FORM A DRUG DELIVERY SYSTEM, HAVING DOSAGE FLEXIBILITY AND STABILITY; TIME-RELEASE AGENTS SHUKLA ATUL J (US) 2002-08-13 US claimed
WO-2002000137-A1 BIODEGRADABLE VEHICLES AND DELIVERY SYSTEMS OF BIOLOGICALLY ACTIVE SUBSTANCES SHUKLA ATUL J (US) 2002-01-03 WO claimed
EP-0516818-B1 IMPROVED MATERIAL FOR MEDICAL GRADE TUBING BAXTER INT (US) 1998-08-12 EP claimed
EP-0138147-B1 CITRATE-ESTER PLASTICIZED PVC BLOOD CONTAINERS Bayer Corporation (US) 1993-04-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137591-A1 COMPOSITIONS AND DEVICES FOR CONTAINING MEDICAL FLUIDS TFEB, LAGE3, RICTOR PLA2G2C 3717/4885S1PR4 4151/4885S1PR1 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.